GlassScriptPhysician profile
Rachel C Ness
NPI 1205031713
$8,178.48
in general payments reported to CMS, 2019-2025
28 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $475 · 2021: $3,775 · 2022: $691 · 2023: $715 · 2024: $874 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.40 |
| Education | $339.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,714.94 | 2020-2021 | |
| Lilly USA, LLC | $887.90 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $800.00 | 2021 | |
| Revance Therapeutics, INC. | $519.80 | 2024-2025 | Daxxify |
| Abbvie INC. | $518.09 | 2019-2025 | |
| Janssen Biotech, INC. | $482.95 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $435.54 | 2019-2024 | Ilumya |
| Galderma Laboratories, L.P. | $315.51 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $229.37 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $204.97 | 2019-2025 | |
| Incyte Corporation | $125.33 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $109.48 | 2022-2024 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Genzyme Corporation | $94.09 | 2019-2023 | |
| Pfizer INC. | $65.92 | 2020-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $65.50 | 2024-2025 | |
| Leo Pharma INC. | $65.30 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $64.82 | 2023-2025 | Zoryve |
| Celgene Corporation | $64.58 | 2019 | |
| Ucb, INC. | $64.48 | 2019-2023 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $44.25 | 2022-2023 | Valchlor |
| Dusa Pharmaceuticals, INC. | $40.46 | 2019 | |
| Amgen INC. | $37.48 | 2020-2021 | |
| Strata Skin Sciences, INC. | $30.91 | 2023-2024 | Xtrac |
| Merck Sharp & Dohme LLC | $30.23 | 2019 | |
| Vyne Pharmaceuticals INC. | $28.11 | 2020 | |
| Dermira, INC. | $19.76 | 2019 | |
| Dermavant Sciences, INC. | $18.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Ness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.